To Study the Function of the Retina in Glaucoma Patients Using PERG
Study Details
Study Description
Brief Summary
The purpose of this trial is to evaluate the performance of a new diagnostic device in the diagnosis and management of glaucoma. We will use this new device (PERG) to evaluate the function of the retina in glaucoma patients. This device is safe for the patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Glaucoma is one of the leading causes of blindness worldwide. It's an optic neuropathy characterized by the progressive death of retinal ganglion cells.
In laboratories, it's possible to measure the electrical activity of retinal ganglion cells (RGC). Some researchers found that RGC showed electrical anomalies before dying. This decrease of electrical activity can be measured by using pattern electroretinography (PERG). Unfortunately, these measures could not be obtained in clinics before this new device.
For this reason, Diopsys developed a new device that can measure PERG directly in clinics, allowing physicians to have these data earlier to help them diagnose pathologies such as glaucoma or other ganglion cells abnormalities.
Currently, it is known that glaucoma is difficult to diagnose in the early stages and it's challenging to decide when to start a treatment.
In this study, our purpose is to use this new device to evaluate its efficacy in the diagnosis and management of glaucoma.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Variability of the device We will study the repeatability and reliability of the Diopsys® ERG Vision Testing Systems in normal non-glaucomatous people and in those with suspicion of glaucoma or confirmed glaucoma. |
|
| Diagnosis and progression of glaucoma Patients who have a suspicion of glaucoma and patients with confirmed glaucoma will be included. PERG data obtained by the Diopsys® ERG Vision Testing Systems will be analyzed to study the PERG changes in different clinical situations, such as early glaucoma and progression of glaucoma. |
|
| Effect of medical/surgical intervention Patients will undergo standard treatment based on their medical history and we will observe the PERG changes induced by these treatments (eye drops, laser or surgery) with the Diopsys® ERG Vision Testing Systems. |
Outcome Measures
Primary Outcome Measures
- Magnitude, μV [4 years]
Strength of the signal
- Magnitude D, μV [4 years]
Strength and phase
- MagD/Mag Ratio (no units) [4 years]
Ratio between MagD and Mag
- SNR, dB [4 years]
Signal to Noise Ratio
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Glaucoma (all types of glaucoma);
-
Ocular hypertensive (Suspicion of glaucoma);
-
Control Patients (without any suspicion/sign of glaucoma);
-
Have given written informed consent, prior to any investigational procedures;
-
Aged 18 years of either sex.
Exclusion Criteria:
-
Patients not able to understand the character of the study
-
Participation in other clinical research within the last 4 weeks
-
Other diseases that may cause visual field loss or optic disc abnormalities
-
Systemic diseases that may affect PERG amplitude such as diabetes, parkinsonism, multiple sclerosis
-
Poor best corrected visual acuity outside the limits recommended for the test
-
Patients with high myopia (>5D)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Montchoisi Clinic | Lausanne | Canton De Vaud | Switzerland | 1006 |
Sponsors and Collaborators
- Swiss Vision Network
Investigators
- Principal Investigator: Kaweh Mansouri, MD, Glaucoma Center, Montchoisi Clinic
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PERG-01